JPWO2019149281A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019149281A5 JPWO2019149281A5 JP2020541916A JP2020541916A JPWO2019149281A5 JP WO2019149281 A5 JPWO2019149281 A5 JP WO2019149281A5 JP 2020541916 A JP2020541916 A JP 2020541916A JP 2020541916 A JP2020541916 A JP 2020541916A JP WO2019149281 A5 JPWO2019149281 A5 JP WO2019149281A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- hvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 115
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 238000003776 cleavage reaction Methods 0.000 claims 9
- 230000007017 scission Effects 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 230000005855 radiation Effects 0.000 claims 8
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 6
- 102000035195 Peptidases Human genes 0.000 claims 6
- 108091005804 Peptidases Proteins 0.000 claims 6
- 239000004365 Protease Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 102000043321 human CTLA4 Human genes 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims 4
- 241000723792 Tobacco etch virus Species 0.000 claims 4
- -1 Trombin Proteins 0.000 claims 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 238000001959 radiotherapy Methods 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 241000282567 Macaca fascicularis Species 0.000 claims 3
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims 2
- 108091007504 ADAM10 Proteins 0.000 claims 2
- 108091007507 ADAM12 Proteins 0.000 claims 2
- 102000029750 ADAMTS Human genes 0.000 claims 2
- 108091022879 ADAMTS Proteins 0.000 claims 2
- 108090000397 Caspase 3 Proteins 0.000 claims 2
- 102000004018 Caspase 6 Human genes 0.000 claims 2
- 108090000425 Caspase 6 Proteins 0.000 claims 2
- 108090000567 Caspase 7 Proteins 0.000 claims 2
- 102100035904 Caspase-1 Human genes 0.000 claims 2
- 108090000426 Caspase-1 Proteins 0.000 claims 2
- 102000004068 Caspase-10 Human genes 0.000 claims 2
- 108090000572 Caspase-10 Proteins 0.000 claims 2
- 102000004066 Caspase-12 Human genes 0.000 claims 2
- 108090000570 Caspase-12 Proteins 0.000 claims 2
- 102000004958 Caspase-14 Human genes 0.000 claims 2
- 108090001132 Caspase-14 Proteins 0.000 claims 2
- 102000004046 Caspase-2 Human genes 0.000 claims 2
- 108090000552 Caspase-2 Proteins 0.000 claims 2
- 102100029855 Caspase-3 Human genes 0.000 claims 2
- 102100025597 Caspase-4 Human genes 0.000 claims 2
- 101710090338 Caspase-4 Proteins 0.000 claims 2
- 102100038916 Caspase-5 Human genes 0.000 claims 2
- 101710090333 Caspase-5 Proteins 0.000 claims 2
- 102100038902 Caspase-7 Human genes 0.000 claims 2
- 102100026548 Caspase-8 Human genes 0.000 claims 2
- 108090000538 Caspase-8 Proteins 0.000 claims 2
- 102000004039 Caspase-9 Human genes 0.000 claims 2
- 108090000566 Caspase-9 Proteins 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 102100039673 Disintegrin and metalloproteinase domain-containing protein 10 Human genes 0.000 claims 2
- 102100031112 Disintegrin and metalloproteinase domain-containing protein 12 Human genes 0.000 claims 2
- 108010014173 Factor X Proteins 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 101000777461 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 17 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 claims 2
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 claims 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 2
- 101000933115 Mus musculus Caspase-4 Proteins 0.000 claims 2
- 101100222220 Mus musculus Ctla4 gene Proteins 0.000 claims 2
- 102100030411 Neutrophil collagenase Human genes 0.000 claims 2
- 101710118230 Neutrophil collagenase Proteins 0.000 claims 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 102100030416 Stromelysin-1 Human genes 0.000 claims 2
- 101710108790 Stromelysin-1 Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 108700005077 Viral Genes Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 229940022399 cancer vaccine Drugs 0.000 claims 2
- 108010018550 caspase 13 Proteins 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 229940012957 plasmin Drugs 0.000 claims 2
- 150000003057 platinum Chemical class 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 238000002626 targeted therapy Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 241000282465 Canis Species 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000000873 masking effect Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023116602A JP7678841B2 (ja) | 2018-02-02 | 2023-07-18 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
| JP2025076560A JP2025124652A (ja) | 2018-02-02 | 2025-05-02 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/075064 | 2018-02-02 | ||
| PCT/CN2018/075064 WO2019148444A1 (en) | 2018-02-02 | 2018-02-02 | Anti-ctla4 antibodies and methods of making and using the same |
| PCT/CN2019/074580 WO2019149281A1 (en) | 2018-02-02 | 2019-02-02 | Anti-ctla4 antibodies and methods of making and using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116602A Division JP7678841B2 (ja) | 2018-02-02 | 2023-07-18 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021511808A JP2021511808A (ja) | 2021-05-13 |
| JP2021511808A5 JP2021511808A5 (https=) | 2022-02-09 |
| JPWO2019149281A5 true JPWO2019149281A5 (https=) | 2022-02-09 |
| JP7413265B2 JP7413265B2 (ja) | 2024-01-15 |
Family
ID=67475181
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541916A Active JP7413265B2 (ja) | 2018-02-02 | 2019-02-02 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
| JP2023116602A Active JP7678841B2 (ja) | 2018-02-02 | 2023-07-18 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
| JP2025076560A Pending JP2025124652A (ja) | 2018-02-02 | 2025-05-02 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116602A Active JP7678841B2 (ja) | 2018-02-02 | 2023-07-18 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
| JP2025076560A Pending JP2025124652A (ja) | 2018-02-02 | 2025-05-02 | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11359016B2 (https=) |
| EP (1) | EP3746486A4 (https=) |
| JP (3) | JP7413265B2 (https=) |
| KR (2) | KR20250131831A (https=) |
| CN (2) | CN112352000B (https=) |
| AU (3) | AU2019214188B2 (https=) |
| BR (1) | BR112020015385B1 (https=) |
| CA (1) | CA3089795A1 (https=) |
| IL (1) | IL276277A (https=) |
| MX (2) | MX2020008075A (https=) |
| SG (1) | SG11202007160PA (https=) |
| TW (1) | TWI829706B (https=) |
| WO (2) | WO2019148444A1 (https=) |
| ZA (2) | ZA202005259B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11643463B2 (en) | 2017-05-19 | 2023-05-09 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| BR112021012536A2 (pt) | 2018-12-26 | 2021-09-14 | City Of Hope | Proteínas de ligação anti-ctla4 mascaradas ativáveis |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| JP7650047B2 (ja) * | 2019-11-27 | 2025-03-24 | 株式会社 MiyaCare Therapeutics | 変異型結合性タンパク質の製造方法及び変異型ｐｄ－１ |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| MY202559A (en) * | 2019-12-27 | 2024-05-08 | Chugai Pharmaceutical Co Ltd | Anti-ctla-4 antibody and use thereof |
| BR112022019841A2 (pt) | 2020-04-09 | 2022-12-06 | Cytomx Therapeutics Inc | Composições contendo anticorpos ativáveis |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| WO2021226883A1 (en) * | 2020-05-13 | 2021-11-18 | Adagene Ag | Compositions and methods for treating cancer submission of sequence listing on ascii text file |
| TW202200622A (zh) | 2020-05-13 | 2022-01-01 | 瑞士商天演藥業公司 | 用於治療癌症之組成物及方法 |
| US20230322953A1 (en) * | 2020-06-30 | 2023-10-12 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
| TWI861258B (zh) * | 2020-10-21 | 2024-11-11 | 日商中外製藥股份有限公司 | 抗ctla-4抗體及其之用途 |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| EP4313147A4 (en) * | 2021-03-28 | 2025-03-19 | Adagene Pte. Ltd. | Methods for treating cancer with anti-CTLA4 antibodies |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AU2022253351A1 (en) | 2021-04-09 | 2023-10-12 | Boehringer Ingelheim International Gmbh | New scaffold for bifunctional molecules with improved properties |
| JP2024517381A (ja) * | 2021-04-11 | 2024-04-22 | アダジーン インコーポレイテッド | がんを治療するための併用療法 |
| US12448451B2 (en) | 2021-06-25 | 2025-10-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
| IL312728A (en) * | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Protease-cleavable masked antibodies |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| EP4581058A2 (en) * | 2022-08-30 | 2025-07-09 | Adagene Pte. Ltd. | Methods for treating cancer using anti-ctla4 antibodies |
| WO2024055005A2 (en) * | 2022-09-09 | 2024-03-14 | Adagene Pte. Ltd. | Activatable anti-ctla4 antibodies for treating cancer |
| CN121358499A (zh) | 2023-03-30 | 2026-01-16 | Ose免疫疗法 | 靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途 |
| AU2024254671A1 (en) | 2023-03-30 | 2025-10-02 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024212152A1 (en) * | 2023-04-13 | 2024-10-17 | Adagene Pte. Ltd. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| DE69233408T2 (de) | 1991-12-02 | 2005-09-22 | Cambridge Antibody Technology Ltd., Melbourn | Herstellung von Antikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken. |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| CN100427603C (zh) | 1999-10-04 | 2008-10-22 | 麦迪卡格公司 | 调控外源基因转录的方法 |
| BRPI0116728B1 (pt) | 2001-01-05 | 2018-10-30 | Pfizer Inc. | anticorpos para receptor de fator de crescimento i semelhante à insulina |
| WO2002055106A2 (en) | 2001-01-09 | 2002-07-18 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| IL160157A0 (en) | 2001-08-17 | 2004-07-25 | Coley Pharm Group Inc | Combination motif immune stimulation oligonucleotides with improved activity |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| CA2477947A1 (en) | 2002-03-01 | 2003-09-12 | Dyax Corp. | Modular recombinatorial display libraries |
| ES2263984T3 (es) | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| AU2003290330A1 (en) | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| US20090005257A1 (en) | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
| CN1845938B (zh) | 2003-06-30 | 2010-05-26 | 杜门蒂斯有限公司 | 多肽 |
| US20060153808A1 (en) | 2004-11-17 | 2006-07-13 | Board Of Regents, The Universtiy Of Texas System | Cancer immunotherapy incorporating p53 |
| DE102004063494A1 (de) | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
| AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| KR20070104673A (ko) * | 2005-03-23 | 2007-10-26 | 화이자 프로덕츠 인코포레이티드 | 암의 치료를 위한 항－ｃｔｌａ４ 항체와 인돌리논병용요법 |
| CA2610661A1 (en) | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| WO2007062093A2 (en) | 2005-11-22 | 2007-05-31 | Incyte Corporation | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| EP2190440A1 (en) | 2007-08-13 | 2010-06-02 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
| AU2013202755B2 (en) | 2007-08-22 | 2016-05-12 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
| CA2697032C (en) * | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| ES2336873B1 (es) | 2007-11-07 | 2011-01-24 | Proyecto De Biomedicina Cima, S.L. | Composicion farmaceutica para el tratamiento de cancer. |
| DK2851374T3 (en) | 2007-12-14 | 2017-06-19 | Bristol Myers Squibb Co | Binding molecules to the human OX40 receptor |
| US20100189651A1 (en) * | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| MX2014016038A (es) | 2012-06-22 | 2015-08-14 | Cytomx Therapeutics Inc | Anticuerpos de reaccion cruzada anti - jagged 1 / jagged 2, anticuerpos anti - jagged activables y metodos para uso de los mismos. |
| WO2014139130A1 (en) | 2013-03-14 | 2014-09-18 | Adagene Inc. | An integrated system for library construction, affinity binder screening and expression thereof |
| CA2925106C (en) | 2013-09-25 | 2023-11-14 | Cytomx Therapeutics, Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| JP7020909B2 (ja) | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス，インコーポレイティド | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 |
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| EP3244907B1 (en) | 2015-01-13 | 2020-02-19 | City of Hope | Ctla4-binding protein peptide-linker masks |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CN108271359B (zh) | 2015-02-13 | 2021-11-09 | 索伦托药业有限公司 | 结合ctla4的抗体治疗剂 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CN107849133B (zh) | 2015-05-04 | 2022-08-23 | 西托姆克斯治疗公司 | 抗cd166抗体、可活化抗cd166抗体及其使用方法 |
| CA2984892A1 (en) | 2015-05-04 | 2016-11-10 | Cytomx Therapeutics, Inc. | Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof |
| US20160362469A1 (en) | 2015-06-12 | 2016-12-15 | Tianxin Wang | Methods for protein modification in pharmaceutical applications |
| CN114591433A (zh) * | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| FI3389699T3 (fi) | 2015-12-15 | 2024-05-28 | Oncoc4 Inc | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| JP7297672B2 (ja) | 2017-04-13 | 2023-06-26 | アジェナス インコーポレイテッド | 抗ｃｄ１３７抗体およびその使用方法 |
| RU2019138067A (ru) | 2017-05-02 | 2021-06-02 | Эллигейтор Биосайенс Аб | Биспецифическое антитело против ox40 и ctla-4 |
| US11643463B2 (en) | 2017-05-19 | 2023-05-09 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| GB201712032D0 (en) | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| SG11202001551YA (en) | 2017-08-21 | 2020-03-30 | Adagene Inc | Dynamic human heavy chain antibody libraries |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| EP3673100A4 (en) | 2017-08-21 | 2021-04-21 | Adagene Inc. | DYNAMIC LIBRARIES FOR HUMAN ANTIBODIES WITH A LIGHT CHAIN |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
-
2018
- 2018-02-02 WO PCT/CN2018/075064 patent/WO2019148444A1/en not_active Ceased
-
2019
- 2019-02-01 US US16/265,946 patent/US11359016B2/en active Active
- 2019-02-02 KR KR1020257027245A patent/KR20250131831A/ko active Pending
- 2019-02-02 SG SG11202007160PA patent/SG11202007160PA/en unknown
- 2019-02-02 CN CN201980022531.1A patent/CN112352000B/zh active Active
- 2019-02-02 AU AU2019214188A patent/AU2019214188B2/en active Active
- 2019-02-02 CA CA3089795A patent/CA3089795A1/en active Pending
- 2019-02-02 MX MX2020008075A patent/MX2020008075A/es unknown
- 2019-02-02 BR BR112020015385-0A patent/BR112020015385B1/pt active IP Right Grant
- 2019-02-02 JP JP2020541916A patent/JP7413265B2/ja active Active
- 2019-02-02 WO PCT/CN2019/074580 patent/WO2019149281A1/en not_active Ceased
- 2019-02-02 CN CN202510230988.9A patent/CN120230212A/zh active Pending
- 2019-02-02 US US16/966,844 patent/US11692036B2/en active Active
- 2019-02-02 EP EP19748085.8A patent/EP3746486A4/en active Pending
- 2019-02-02 KR KR1020207024942A patent/KR102848310B1/ko active Active
- 2019-06-10 TW TW108119978A patent/TWI829706B/zh active
-
2020
- 2020-07-26 IL IL276277A patent/IL276277A/en unknown
- 2020-07-30 MX MX2025000370A patent/MX2025000370A/es unknown
- 2020-08-24 ZA ZA2020/05259A patent/ZA202005259B/en unknown
-
2023
- 2023-05-18 US US18/320,146 patent/US20240141046A1/en active Pending
- 2023-07-12 AU AU2023204604A patent/AU2023204604B2/en active Active
- 2023-07-18 JP JP2023116602A patent/JP7678841B2/ja active Active
- 2023-08-18 ZA ZA2023/08021A patent/ZA202308021B/en unknown
-
2024
- 2024-06-07 AU AU2024203885A patent/AU2024203885A1/en active Pending
-
2025
- 2025-05-02 JP JP2025076560A patent/JP2025124652A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021511808A5 (https=) | ||
| JPWO2019149281A5 (https=) | ||
| KR102068600B1 (ko) | Pdl-1 항체, 그 약학적 조성물 및 그 용도 | |
| CN112352000B (zh) | 抗ctla4抗体及其制备和使用方法 | |
| JP6759508B2 (ja) | Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療 | |
| US20220041744A1 (en) | Cd73 blocking antibodies | |
| US12583932B2 (en) | CD38 and ICAM1 antibodies and uses thereof | |
| WO2022170619A1 (en) | Anti-cd3 antibodies and methods of use thereof | |
| TW202515920A (zh) | 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法 | |
| CN121046961A (zh) | 可活化抗体及其制备和使用方法 | |
| US20200157224A1 (en) | Multi-specific antibodies and methods of making and using thereof | |
| CN111886255B (zh) | 抗tim3抗体及其用途 | |
| JPWO2020252264A5 (https=) | ||
| US20230124669A1 (en) | Heterodimeric proteins with fc mutations | |
| US20220220219A1 (en) | Affinity maturated tag72 specific single chaing antibodies | |
| CN114269784A (zh) | 具有选择性可切割接头的双特异性结合构建体 | |
| WO2022127066A1 (zh) | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 | |
| US20250326847A1 (en) | Activatable anti-ctla4 antibodies for treating cancer | |
| JPWO2023193817A5 (https=) | ||
| US20240392026A1 (en) | Agonistic cd40 antibodies as immune stimulatory agents | |
| AU2023375570A1 (en) | Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof | |
| CN121263443A (zh) | 抗ctla4抗体及其制备和使用方法 | |
| KR20220143904A (ko) | 사람 4-1bb 항진제 항체 및 이의 사용 방법 | |
| NZ767462B2 (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| NZ807606A (en) | Anti-ctla4 antibodies and methods of making and using the same |